Advertisement


Bridgett Harr, CNP, on Reducing ER Visits and Admissions in High-Risk Head and Neck Cancer Patients

2015 ASTRO Annual Meeting

Advertisement

Bridgett Harr, CNP, of Cleveland Clinic, discusses the advanced practice nurse follow-up clinic, which focuses on symptom management in the first 90 days postchemoradiation (Abstract 3169).



Related Videos

Lung Cancer
Pain Management

Brian D. Kavanagh, MD, on Improving Value and Elevating the Patient Care Experience

Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided intensity-modulated radiotherapy for reducing bowel toxicity, and dexamethasone for controlling pain flares in patients with bone metastases (Abstracts 2, 8, LBA6663).

Symptom Management
Palliative Care
Pain Management

Samuel Chao, MD, on Improving the Consistency of Radiation Oncology Processes

Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).

Breast Cancer

Jay Harris, MD, on Making Sense of Conflicting Data on Breast Irradiation

Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.

Lung Cancer

Stephen G. Chun, MD, on NSCLC: Results From NRG Oncology/RTOG 0617

Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).

Gastroesophageal Cancer
Colorectal Cancer

Leonard Gunderson, MD, on the Presidential Symposium Lecture on Upper and Lower GI Cancers

Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse after a complete response to treatment.

Advertisement

Advertisement




Advertisement